Moderna has announced the start of its Phase 1/2 human clinical trial involving its mRNA seasonal influenza vaccine. The work is the start of what may prove to be an interesting evolution in seasonal illness vaccines, with Moderna stating that it plans to evaluate possible combination vaccines that would offer protection from RSV, influenza, COVID-19, and hMPV. According to Moderna, …
Moderna has announced the start of its Phase 1/2 human clinical trial involving its mRNA seasonal influenza vaccine. The work is the start of what may prove to be an interesting evolution in seasonal illness vaccines, with Moderna stating that it plans to evaluate possible combination vaccines that would offer protection from RSV, influenza, COVID-19, and hMPV. According to Moderna, …
Share this Article
Recommended